secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2025-10-22T23:59:59+00:00
Accession:  0001193805-25-001499
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus reports ARCT-032 CF interim data showing mucus reduction; KOSTAIVE BLA submission delayed by FDA
--------------------------------------------------------------------------------

- ARCT-032 Phase 2 interim: generally safe/tolerated; 4 of 6 Class I CF patients showed mucus plug/volume reduction after 28 days (10 mg).
- FDA requested delay of KOSTAIVE BLA submission (Sep 5), then required additional clinical endpoint efficacy study per updated COVID-19 framework.
- CSL Seqirus submitted KOSTAIVE MAA to UK MHRA in June 2025; approval expected Q1 2026, but not assured.
- Company filed lawsuit Sep 23, 2025 against AbbVie and Capstan Therapeutics for trade secret misappropriation and breach of contract.
- 12-week safety/efficacy study of ARCT-032 in up to 20 CF participants planned to start first half of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380525001499/0001193805-25-001499-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380525001499/e664913_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-25-001499

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer